首页> 外文期刊>Experimental and clinical transplantation >Risk Factors of Long-Term Graft Loss in Renal Transplant Recipients with Chronic Allograft Dysfunction
【24h】

Risk Factors of Long-Term Graft Loss in Renal Transplant Recipients with Chronic Allograft Dysfunction

机译:慢性同种异体移植肾功能不全的肾移植患者长期移植物丢失的危险因素

获取原文
           

摘要

Background: Graft loss owing to chronic allograft dysfunction is a major concern in renal transplant recipients. We assessed the affect of immune and nonimmune risk factors on death-censored graft loss in renal transplant recipients with chronic allograft dysfunction. Materials and Methods: We performed a retrospective, single-center study on 214 renal transplant recipients with chronic allograft dysfunction among 1534 renal transplant recipients at the Urmia University Hospital from 1997 to 2005. Data registry includes details from all renal transplants. The renal transplant recipient information is regularly updated to determine current graft function, graft loss, or renal transplant recipient’s death. The selection criteria were a functional renal allograft for at least 1 year and a progressive decline in allograft function. Results: Increasing donor age (RR=1.066; P < .001), recipient age (RR=1.021, P = .0), recipient weight (RR=1.024; P = .029), and waiting time on dialysis to transplant. (RR=1.047; P = .006), pretransplant hypertension (RR=3.126; P < .001), pretransplant diabetes (RR=5.787; P < .001), delayed graft function (RR=6.087; P < .001), proteinuria (RR=2.663; P = .001), posttransplant diabetes (RR=2.285; P = .015), posttransplant hypertension (RR=2.047; P = .017), and AR (RR=3.125; P < .001). Patients in stage 2 at the beginning of chronic allograft dysfunction relative to stage 1 (RR=4.823; P < .001) and patients in stage 3 at the beginning of chronic allograft dysfunction relative to stage 1 (RR=123.06; P < .001) were significant risk factors for death-censored graft loss. Using mycophenolate mofetil versus azathioprine reduced death-censored graft loss (RR=0.499; P ≤ .001). Conclusion: We found that age of donor, pretransplant hypertension, pretransplant diabetes, type of immunosuppression (mycophenolate mofetil vs azathioprine), delayed graft function, proteinuria, and stage of allograft dysfunction at the start of chronic allograft dysfunction are the major risk factors for late renal allograft dysfunction.
机译:背景:由于慢性同种异体移植功能障碍导致的移植损失是肾移植接受者的主要关注。我们评估了免疫和非免疫危险因素对具有慢性同种异体移植功能障碍的肾移植受者进行以死亡检查的移植物损失的影响。材料和方法:我们从1997年至2005年在Urmia大学医院的1534名肾移植受者中,对214名患有慢性同种异体移植功能障碍的肾移植受者进行了一项回顾性,单中心研究。数据注册表包括所有肾移植的详细信息。肾移植接受者的信息会定期更新,以确定当前的移植功能,移植物丢失或肾移植接受者的死亡。选择标准为功能性同种异体肾移植至少1年,同种异体移植功能逐渐下降。结果:增加供体年龄(RR = 1.066; P <.001),受体年龄(RR = 1.021,P = .0),受体体重(RR = 1.024; P = .029)以及透析透析的等待时间。 (RR = 1.047; P = .006),移植前高血压(RR = 3.126; P <.001),移植前糖尿病(RR = 5.787; P <.001),移植物功能延迟(RR = 6.087; P <.001) ,蛋白尿(RR = 2.663; P = .001),移植后糖尿病(RR = 2.285; P = .015),移植后高血压(RR = 2.047; P = .017)和AR(RR = 3.125; P <.001 )。相对于1期处于慢性同种异体移植功能障碍初期的2期患者(RR = 4.823; P <.001)和相对于1期处于慢性同种异体移植功能障碍初期的3期患者(RR = 123.06; P <.001 )是死亡检查的移植物丢失的重要危险因素。 Mofetil霉酚酸酯和硫唑嘌呤的使用减少了死亡检查的移植物丢失(RR = 0.499; P≤.001)。结论:我们发现供者的年龄,移植前高血压,移植前糖尿病,免疫抑制类型(霉酚酸酯,硫唑嘌呤),移植物功能延迟,蛋白尿和同种异体移植功能障碍在慢性同种异体移植功能障碍开始时的阶段是晚期发生的主要危险因素。肾脏同种异体功能障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号